Recent developments in the management of haemophagocytic lymphohistiocytosis

REFERENCES

• HENTER J-I, ELINDER G, OST A: Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin. Oricol. (1991) 18:29-33 •The diagnostic criteria in this report has been cited in many articles and employed widely and internationally.
   Google Scholar
• IMASHUKU S: Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int. j Hematol. (1997) 66:135-151. •Underlying disorders causing haemophagocytic syndrome in children and adults were described in details. Also a revised diagnostic criteria useful for both paediatric and adult patients was proposed.
   Google Scholar
• IMASHUKU S: Advances in the management of hemophagocytic lymphohistiocytosis. mt. j Hematol. (2000) 72:1–11.
   Google Scholar
• TSUDA H: Hemophagocytic syndrome (HPS) in children and adults. Int. Hematol. (1997) 65:215–226.
   PubMed Web of Science ®Google Scholar
• KUMAKURA S, ISHIKURA H, UMEGAE N, YAMAGATA S, KOBAYASHI S: Autoimmune-associated hemophagocytic syndrome. Am. j Med. (1997) 102:113–115.
   PubMed Web of Science ®Google Scholar
• DUVAL M, FENNETEAU 0, DOIREAU V et al.: Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. I Pediatr. (1999) 134:236–239
   Google Scholar
• JANKA GE: Familial hemophagocytic lymphohistiocytosis. Eur. j Pediatr. (1983) 140:221–230.
   PubMed Web of Science ®Google Scholar
• ARICO M, JANKA G, FISCHER A et al.:Hemophagocytic lymphohistiocytosis: Diagnosis, treatment, and prognostic factors. Report of 122 children from the international registry. Leukaemia (1996) 10:197-203. •Clearly demonstrated that FHL patients can survive only with SCT. If untransplanted, their prognosis was very poor.
   Google Scholar
• SEEMAYER TA, GROSS TG, EGELERRM et al.: X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. (1995) 38:471–478.
   PubMed Web of Science ®Google Scholar
• HADDAD E, LE DEIST E BLANCHE S et al.: Treatment of Chediak-Higashi syndrome by allogeneic bone marrow transplantation: report of 10 cases. Blood (1995) 85:3328–3333.
   Google Scholar
• CERTAIN S, BARRAT F, PASTURAL E etal.: Protein truncation test of LYST reveals heterogeneous mutations in patients with Chediak-Higashi syndrome. Blood (2000) 95:979–83
   Google Scholar
• KLEIN C, PHILIPPE N, LE DEIST F etal.: Partial albinism with immunodeficiency (Girscelli syndrome). I Pediatr (1994) 125:886–895
   Google Scholar
• HORN KD: Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). QJM(1998) 91:265–277
   PubMed Web of Science ®Google Scholar
• SULLIVAN KE, DELAAT CA, DOUGLAS SD, FILIPOVICH AH: Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. PedMtr. Res. (1998) 44:465–468.
   PubMed Web of Science ®Google Scholar
• HARTUNG K, LE BLANC S, FRANZ A etal.: Severe chronic Epstein-Barr virus infection with natural killer cell defect. Deutsch Med. Wochenschr. (1988) 113:1960–1963.
   Google Scholar
• IMASHUKU S, HIBI S, TABATA Y et al.: Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med. Pediatr. Oricol. (1998) 31:131–137.
   PubMedGoogle Scholar
• OHADI M, LALLOZ MR, SHAM P etal.: Localization of a gene for familial hemophagocytic lymphohisitiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am. j Hum. Genet. (1999) 64:165–171.
   Google Scholar
• DUFOURCQ-LAGELOUSE R, JABADO N, LE DEIST F et al.: Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Am. J Hum. Genet. (1999) 64:172–179.
   Google Scholar
• GRAHAM GE, GRAHAM LM, BRIDGE PJ et al.: Further evidence for genetic heterogeneity in familial hemophagocytic lymphohistiocytosis. Pediatr. Res. (2000) 48:227–232.
   PubMed Web of Science ®Google Scholar
• STEPP SE, DUFOURCQ-LAGELOUSE R, LE DEIST F et al.: Perform n gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286:1957-1959. •Among the genes responsible for FHL, the one localised at 10q21-22 was identified as the perforin gene. The molecular diagnosis of FHL first became possible by studying perforin protein or perforin gene in the
   Google Scholar
• COFFEY AJ, BROOKSBANK RA, BRANDAU 0 et al.: Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an 5H2-domain encoding gene. Nature Genetics (1998) 20:129-135. •Identified the gene responsible for XLP. The molecular diagnosis of XLP is now possible at the bedside by studying SAP protein.
   Google Scholar
• SAYOS J, WU C, MORRA M et al.: The X- linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 395:462-469. •Identified the gene responsible for XLP.
   Google Scholar
• NICHOLS KE, HARKIN DP, LEVITZ S et al.: Inactivating mutations in an 5H2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Nati Acad. Sci. USA (1998) 95:13765-13770. •Identified the gene responsible for XLP.
   Google Scholar
• BROWN RE, BOWMAN WP, D'CRUZ CA, PICK TE, CHAMPION JE: Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis: Reversal with VP16 and indomethacin. Cancer (1987) 60:2388–2393.
   PubMed Web of Science ®Google Scholar
• BAARS JW, DE BOER JP, WAGSTAFF Jetal.: Interleukin-2 induced activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br j Haematol. (1992) 82:295–301.
   Google Scholar
• HAMILTON JA, WHITTY GA, STANTON H et al.: Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood (1993) 82:3616–3621.
   PubMedGoogle Scholar
• SHINMYOZU K, MURAYAMA I, OSAME M: Coagulation and fibrinolytic abnormalities in the mononuclear phagocyte system proliferative disorders-with special reference to hemophagocytic histiocytic syndrome...J..1pr] Soc. Lymphoretic Tissue Res. (1991) 31:55–71.
   Google Scholar
• HADDAD E, SULIS ML, JABADO N et al.: Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood (1997) 89:794-800. •Important article describing CNS lesions in HLH.
   Google Scholar
• KESSELRING J, MILLER DH, ROBB SAet al.: Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 113:291–302.
   Google Scholar
• HOWELLS DW, STROBEL S, SMITH I, LEVINSKY RJ, HYLAND K: Central nervous system involvement in the erythrophagocytic disorders of infancy: the role of cerebrospinal fluid neopterins in their differential diagnosis and clinical management. Pediatr. Res. (1990) 28:116–119.
   PubMed Web of Science ®Google Scholar
• ESUMI N, IKUSHIMA S, HIBI S, TODO S, IMASHUKU S: High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer (1988) 61:2071-2076. •First article reported serum ferritin as a macrophage activation marker.
   Google Scholar
• HIBI S, IKUSHIMA S, FUJI WARA F et al.: Serum and urine beta-2-microglobulin in hemophagocytic syndrome. Cancer (1995) 75:1700–1705.
   Google Scholar
• HASEGAWA D, KOJIMA S, TATSUMI E et al.: Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood (1998) 91:2793–2799.
   PubMed Web of Science ®Google Scholar
• FADEEL B, ORRENIUS S, HENTER JI: Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. Br j Haematal. (1999) 106:406–415.
   PubMed Web of Science ®Google Scholar
• EMMENEGGER U, ZEHNDER R, FREY U et al: Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes. Am. I Hematal (2000) 64:116–119.
   PubMed Web of Science ®Google Scholar
• OHSHIMA K, SHIMAZAKI K, SUGIHARA M etal.: Clinicopathological findings of virus-associated hemophagocytic syndrome in bone marrow association with Epstein-Barr virus and apoptosis. Pathol. Int. (1999) 49:533–540.
   Google Scholar
• KIMURA H, MORITA M, YABUTA Y et al.: Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. Chu. Microbial (1999) 37:132–136.
   PubMed Web of Science ®Google Scholar
• STARK B, COHEN IJ, PECHT M et al:Immunologic dysregulation in a patient with familial hemophagocytic lymphohistiocytosis. Cancer (1987) 60:2629–2636.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HIBI S, SAKO M et al.:Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood (1995) 86:4706–4707.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HIBI S, FUJIWARA F, IKUSHIMA S, TODO S: Haemophagocytic lymphohistiocytosis, inferferon-gamma-naemia and Epstein-Barr virus involvement. Br j Haematal. (1994) 88:656–658.
   PubMed Web of Science ®Google Scholar
• OSUGI Y, HARA J, TAGAWA S et al: Cytokine production regulating Thl and Th2 cytokines in hemophagocytic lymphohistiocytosis. B./nor/(1997) 89:4100–4103.
   Google Scholar
• AKASHI K, HAYASHI S, GONDO H et al.: Involvement of interferon-y and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br Haematal. (1994) 87:243–250.
   PubMed Web of Science ®Google Scholar
• TAKADA H, OHGA S, MIZUNO Y et al:Oversecretion of IL-18 in hemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br I Haematal. (1999) 106:182–189.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA K, OKAMOTO H, WATANABE M, SUYAMA T, MIZUSHIMA Y: Development of a corticosteroid incorporated in lipid microspheres (liposteroid). Drugs Exp. Chu. Res. (1985) 11: 611–620.
   PubMed Web of Science ®Google Scholar
• BONANOMI MH, VELVART M, STIMPEL M et al: Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatal. Int. (1987) 7:203–212.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HIBI S, OHARA T et al:Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood (1999) 93:1869-1874. •Multi-centre study demonstrated the effectiveness of the HLH-94 protocol for EBV-HLH.
   Google Scholar
• YAMAMOTO H, ASOH M, MURAKAMI H, KAMIYAMA N, OHTA C: Liposteroid (dexamethasone palmitate) therapy for West syndrome: a comparative study with ACTH therapy. Pediatr. Neural. (1998) 18:415–419.
   PubMed Web of Science ®Google Scholar
• GILL DS, SPENCER A, COBCROFT RG: High-dose gamma globulin therapy in the reactive haemophagocytic syndrome. Br Haematal. (1994) 88:204–206.
   PubMed Web of Science ®Google Scholar
• GOULDERP, SEWARD D, HATTON C: Intravenous immunoglobulin in virus associated haemophagocytic syndrome. Arch. Dis. Child (1990) 65:275–277.
   PubMed Web of Science ®Google Scholar
• FREEMAN B, RATHORE MH, SALMAN E, JOYCE MJ, PITEL P: Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. Pediatr. (1993) 123:479–481.
   Web of Science ®Google Scholar
• NOMURA S, KOSHIKAWA K, HAMAMOTO K, OKUBO S, YASUNAGA K: Steroid and gamma globulin therapy against virus-associated hemophagocytic syndrome. Rimy° Ketsueki (1992) 33:1242–1247.
   PubMedGoogle Scholar
• MARUSAWA H, HAMAMOTO K: Virus-associated hemophagocytic syndrome due to rubella virus in an adult. Rinsho Ketsueki (1994) 35:576–580.
   PubMedGoogle Scholar
• CHEN RL, LIN KH, LIN DT etal.: Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br. Haematal. (1995) 89:282–290.
   Google Scholar
• IMASHUKU S, KURIYAMA K, TERAMURA T et al.: Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. I Chu. Oncol. (2001) 19:2665-2673. •The study clarified the necessity of etoposide in the treatment of EBV-HLH.
   Google Scholar
• NAGASAWA M, OKAWA H, YATA J: Deleterious effects of high dose gamma-globulin therapy on patients with hemophagocytic syndrome. Int. I Hematal (1994) 60:91–93.
   PubMed Web of Science ®Google Scholar
• AUKRUST P, FROLAND SS, LIABAKK NB et al.: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vitro. B./nor/(1994) 84:2136–2143.
   Google Scholar
• BLASCZYK R, WESTHOFF U, GROSSE-WILDE H: Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet (1993) 341:789–790.
   PubMed Web of Science ®Google Scholar
• LAM L, WHITSETT CF, MCNICHOLL JM, HODGE TW, HOOPER J: Immunologically active protein in intravenous immunoglobulin. Lancet (1993) 342:678.
   PubMed Web of Science ®Google Scholar
• FINSTERER J, GRASS R, STOLLBERGER C, MAMOLI B: Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Chu. Neurapharmacol (1998) 21:258–261.
   PubMed Web of Science ®Google Scholar
• SAHLAS DJ, MILLER SP, GUERIN M,VEILLEUX M, FRANCIS G: Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology (2000) 54:1370–1372.
   PubMed Web of Science ®Google Scholar
• DAABOUL Y, VERN BA, BLEND MJ: Brain SPECT imaging and treatment with IVIG in acute post-infectious cerebellar ataxia: case report. Neural Res. (1998) 20:85–88.
   PubMed Web of Science ®Google Scholar
• HO S, CLIPSTONE N, TIMMERMANN L et al.: The mechanisms of action of cyclosporin A and FK506. Clin. Immune]. Immurropathol. (1996) 80:S40–45.
   PubMedGoogle Scholar
• SANTORI L, RASTELLI M, ARENA B, MORLEO MA: Cyclosporine: update on pharmacology, analytical techniques and therapeutic monitoring. Boll. Chim. Farm. (1997) 136:577–588.
   PubMedGoogle Scholar
• OYAMA Y, AMANO T, HIRAKAWA S et al.: Haemophagocytic syndrome treated with cyclosporin A: T cell disorder? Br Haematal. (1989) 73:276–278.
   Google Scholar
• TSUDA H: The use of cyclosporin-A in thetreatment of virus-associated hemophagocytic syndrome in adults. Leuk. Lymphoma (1997) 28:73–82.
   PubMed Web of Science ®Google Scholar
• BADER-MEUNIER B, PAREZ N, MULLER S: Treatment of hemophagocytic lymphohistiocytosis with cyclosporin A and steroids in a boy with lysinuric protein intolerance. j Pediatr: (2000) 136:134.
   PubMed Web of Science ®Google Scholar
• SOOD R, STEWART CC, APLAN PD et al.: Neutropenia associated with T-cell large granular lymphocyte leukemia: Long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood (1998) 91:3372–3378.
   PubMed Web of Science ®Google Scholar
• HERROD HG, WANG WC, SULLIVAN JL: Chronic T-cell lymphocytosis with neutropenia. Its association with Epstein-Barr virus infection. Am. j Dis. Child (1985) 139:405–407.
   PubMedGoogle Scholar
• GARIPIDOU V, TSATALAS C, SINACOS Z: Severe neutropenia in a patient with large granular lymphocytosis: prolonged successful control with cyclosporin A. Haematologica (1991) 76:424–425.
   PubMed Web of Science ®Google Scholar
• JAKUBOWSKI A, WINTON EF, GENCARELLI A, GABRILOVE J: Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine A and filgrastim. Am. Hematal. (1995) 50:288–291.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HIBI S, KURIYAMA K et al.: Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH). Leuk. Lymphoma (2000) 36:339–346.
   PubMed Web of Science ®Google Scholar
• ABELLA EM, ARTRIP J, SCHULTZ K, RAVINDRANATH Y: Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. Pediatr. (1997) 130:467–470.
   Web of Science ®Google Scholar
• HENTER JI, ARICO M, EGELER RIVI et al.: HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med. Pediatr. Orical. (1997) 28:342-347. •More than 200 cases were registered for this first international and multi-centre treatment protocol for HLH.
   Google Scholar
• NISHIGAKI Y, INOUE M, JIMI T, WAKAYAMA Y, YOSHIBA M: Reversible posterior leukoencephalopathy in a patient receiving cyclosporin therapy. Rinsho Shinkeigaku (1999) 39:360–363.
   PubMedGoogle Scholar
• SHIMIZU C, KIMURA S, YOSHIDA Yet al.: Acute leukoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome. Pediatr. Nephrol. (1994) 8:483–485.
   Google Scholar
• STEPHAN JL, DONADIEU J, LEDEIST F et al.: Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood (1993) 82:2319–2323.
   PubMed Web of Science ®Google Scholar
• PEREL Y, ALOS N, ANSOBORLO S, CARRERE A, GUILLARD JM: Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome. Arch. Paediatr. (1997) 86:911.
   Google Scholar
• FISCHER A, VIRELIZIER JL, ARENZANA-SEISDEDOS F et al: Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of VP16-213, steroids, intrathecal methotrexate and cranial irradiation. Pediatrics (1985) 76:263–268.
   PubMed Web of Science ®Google Scholar
• ALARCON GS: Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immurropharmacology (2000) 47:259–271.
   PubMedGoogle Scholar
• KENDRA JR: Methotrexate therapy to alleviate anaemia in a patient with large granular lymphocytosis. Br. I Haematal (1998) 101:592–596.
   Web of Science ®Google Scholar
• AMBRUSO DR, HAYS T, ZWARTJES WJ, TUBERGEN DG, FAVARA BE: Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer (1980) 45:2516–2520.
   PubMed Web of Science ®Google Scholar
• LOECHELT BJ, EGELER M, FILIPOVICH AFL JYONOUCHI H, SHAPIRO RS: Immunosuppression: preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL). Med. Pediatr. arca (1994) 22:325–328.
   Google Scholar
• BEJAOUI M, VEBER E GIRAULT D et al.: The accelerated phase of Chediak-Higashi syndrome. Arch. Fr. Pediatr: (1989) 46:733–736.
   Google Scholar
• KIKUTA H, SAKIYAMA Y: Etoposide (VP16) inhibits Epstein-Barr virus determined nuclear antigen (EBNA) synthesis. Br. J. Haematal. (1995) 90:971–973.
   PubMedGoogle Scholar
• SU IJ, WANG CH, CHENG AL, CHEN RL: Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk. Lymphoma (1995) 19:401–406.
   PubMed Web of Science ®Google Scholar
• HENTER JI, NENNESMO I: Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. Pediatr. (1997) 130:358-365. •Important article describing the neuropathological findings of CNS lesions in HLH.
   Google Scholar
• AKIMA M, SUMI SM: Neuropathology of familial erythrophagocytic lymphohistiocytosis: six cases and review of the literature. Hum. Pathol. (1984) 15:161–168.
   PubMed Web of Science ®Google Scholar
• SHUPER A, ATTIAS D, KORNREICH L, ZAIZOV R, YANIV I: Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation. Pediatr. (1998) 133:126–128.
   Web of Science ®Google Scholar
• CALDEMEYER KS, SMITH RR, HARRIS TM, EDWARDS MK: MRI in acute disseminated encephalomyelitis. Neuraradialogy (1994) 36:216–220.
   PubMed Web of Science ®Google Scholar
• DATTA AK, COLBY BM, SHAW JE, PAGANO JS: Acyclovir inhibition of Epstein-Barr virus replication. Proc. Natl. Acad. Sci. USA (1980) 77:5163–51636.
   PubMed Web of Science ®Google Scholar
• TORRE D, TAMBINI R: Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scant/. j Infect. Dis. (1999) 31:543–547.
   PubMed Web of Science ®Google Scholar
• TYNELL E, AURELIUS E, BRANDELL A et al.: Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. j Infect. Dis. (1996) 174:324–331.
   PubMed Web of Science ®Google Scholar
• VAN DER HORST C, JONCAS J, AHRONHEIM G et al.: Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. j Infect. Dis. (1991) 164:788–792.
   Google Scholar
• ANDERSSON J, ERNBERG I: Management of Epstein-Barr virus infections. Am. J. Med. (1988) 85:107–15
   PubMed Web of Science ®Google Scholar
• DELONE P, CORKILL J, JORDAN M et al.: Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplant. Proc. (1995) 27:58–59.
   PubMed Web of Science ®Google Scholar
• SOFUE A, KINOSHITA T, NISIZAKI A et al.: A case of Epstein-Barr virus associated hemophagocytic syndrome treated with vidarabine. I Jim Pediatr. Soc. (2001) 105:33–36.
   Google Scholar
• OKAJIMA K, UCHIBA M: The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semi]. Thromb. Hemost. (1998) 24:27–32.
   PubMed Web of Science ®Google Scholar
• ILIAS W, LIST W, DECRUYENAERE J et al.: Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med. (2000) 26:704–715.
   PubMed Web of Science ®Google Scholar
• OPAL SM: Therapeutic rationale for antithrombin III in sepsis. Grit. Care Med. (2000) 28:S34–37.
   Web of Science ®Google Scholar
• BARGETZI MJ, WORTELBOER M, PABST T et al: Severe neutropenia in T-large granular lymphocyte leukemia corrected by intensive immunosuppression. Ann. Hematol. (1996) 73:149–151.
   PubMed Web of Science ®Google Scholar
• AZUMA E, TABATA N, SHIBATA T et al.: G-CSF enhanced granulocyte production in a child with severe neutropenia in the setting of fatal virus associated hemophagocytic syndrome. Am. Hematol (1990) 35:266–268.
   PubMed Web of Science ®Google Scholar
• TSUDA H, SHIRONO K: Successful treatment of virus-associated haemophagocytic syndrome in adults by cyclosporin A supported by granulocyte colony-stimulating factor. Br j Haematol (1996) 93:572–575.
   PubMed Web of Science ®Google Scholar
• GILMORE GL, DEPASQUALE DK, FISCHER BC, SHADDUCK RK: Enhancement of monocytopoiesis by granulocyte colony-stimulating factor: evidence for secondary cytokine effects in vivo. Exp. Hematol (1995) 23:1319–1323.
   PubMed Web of Science ®Google Scholar
• DEMUYNCK H, ZACHEE P, VERHOEF GE etal.: Risks of rhG-CSF treatment in drug induced agranulocytosis. Ann. Hematol (1995) 70:143–147.
   Google Scholar
• IERASHIMA T, KANAZAWA M, SAYAMA K et al.: Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am. j Respir. Grit. Care Med. (1994) 149:1295–1303.
   PubMed Web of Science ®Google Scholar
• INOUE H, USUBA A, ENDO Y et al: The effect of protease inhibitors in shock. Nippon Ceka Cakkai Zasshi (1989) 90:1374–1377.
   PubMedGoogle Scholar
• NAKAMURA K, ONITSUKA T, YANO M etal.: Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura. Ann. Thorac. Surg. (2000) 70:2161–2163.
   Google Scholar
• NOVELLI GP, CASALI R, BONIZZOLI M etal.: Antioxidant action of FOY in an experimental model of hypergeneration of oxygen free radicals. lVlinerva Arrestesiol (1996) 62:403–407.
   Google Scholar
• NAWATA R, AMITANI R, IKEGAMI Y et al: Study of effect of ulinastatin for pulmonary aspergillosis model mice. I fpri Assoc. Infect. Dis. (1996) 70:989–990.
   Google Scholar
• CANELLOS GP, ANDERSON JR, PROPERT KJ et al.: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. (1992) 327:1478–1484.
   PubMed Web of Science ®Google Scholar
• SPIEKER T, KURTH J, KUPPERS R et al: Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease. Blood (2000) 96:3133–3138.
   PubMed Web of Science ®Google Scholar
• ENGEL M, ESSOP ME CLOSE P etal.: Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. Pathol. (2000) 53:182–186.
   Google Scholar
• ALEXANDER FE, JARRETT RF, LAWRENCE D et al.: Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br. J. Cancer (2000) 82:1117–1121.
   PubMed Web of Science ®Google Scholar
• SHIMAZAKI C, INABA T, NAKAGAWA M: B-cell lymphoma-associated hemophagocytic syndrome. Leuk. Lymphoma (2000) 38:121–130.
   PubMed Web of Science ®Google Scholar
• WILLIAMS LL, ROONEY CM, CONLEY ME et al: Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet (1993) 342:587-588. •Demonstrated that SCT was essential to promise a cure in patients with XLP, further suggesting the necessity of SCT in other EBV-related disorders.
   Google Scholar
• PRACHER E, GRUMAYER-PANZER ER, ZOUBEK A, PETERS C, GADNER H: Bone marrow transplantation during fulminant EBV-infection in Duncan's syndrome. Lancet (1993) 342:1362. •Demonstrated that SCT was essential to promise a cure in patients with XLP, further suggesting the necessity of SCT in other EBV-related disorders.
   Google Scholar
• VOWELS MR, TANG RL, BERDOUKAS V et al: Brief report: Correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl. J. Med. (1993) 329:1623-1625. •Demonstrated that SCT was essential to promise a cure in patients with XLP, further suggesting the necessity of SCT in other EBV-related disorders.
   Google Scholar
• BOLME P, HENTER JI, WINIARSKI J et al.: Allogeneic bone marrow transplantation in hemophagocytic lymphohistiocytosis in Sweden. Bone Marrow Transplant (1995) 15:331–335.
   PubMed Web of Science ®Google Scholar
• BAKER KS, DELAAT CA, STEINBUCH M et al.: Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood (1997) 89:3857–3863.
   PubMed Web of Science ®Google Scholar
• DURKEN M, HORSTMANN M, BIELING P et al: Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br j Haematol (1999) 106:1052–1058.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HIBI S, TODO S et al.: Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant. (1999) 23:569–572.
   PubMed Web of Science ®Google Scholar
• OKAMURA T, HATSUKAWA Y, ARAI H, INOUE M, KAWA K: Blood stem cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet (2000) 356:223–224.
   PubMed Web of Science ®Google Scholar
• FUJII N, TAKENAKA K, HIRAM A etal.: Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant. (2000) 26:805–808.
   Google Scholar
• IMASHUKU S, TABATA Y, rIERAMURA T, HIBI S: Hemophagocytic syndrome in relation to NK/T neoplasmas - Clinical features of NK-cell type hemophagocytic lymphohistiocytosis (NK-HLH) . Hematology & Oncology (2000) 40:99-100 (in Japanese).
   Google Scholar
• LEVY J, WODELL RA, AUGUST CS, BAYEVER E: Adenovirus-related hemophagocytic syndrome after bone marrow transplantation. Bone Marrow Transplanr (1990) 6:349–352.
   PubMed Web of Science ®Google Scholar
• REARDON DA, ROSKOS R, HANSON CA, CASTLE V: Virus-associated hemophagocytic syndrome following bone marrow transplantation. Am. j Pediatr. Hematol Oncol (1991) 13:305–309.
   PubMedGoogle Scholar
• FUKUNO K, TSURUMI H, YAMADA T, OYAMA M, MORIWAKI H: Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation. Int. j Hematol (2001) 73:262–265.
   PubMed Web of Science ®Google Scholar
• CHAN KW, MULLEN CA, KORBLING M: Allogeneic peripheral blood stem celltransplantation for active hemophagocytic lymphohistiocytosis. Bone Marrow Transplanr (1998) 22:301–302.
   PubMed Web of Science ®Google Scholar
• OHGA S, NOMURA A, KAI T et al: Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablasive chemotherapy and subsequent autologous peripheral blood stem cell transplantation. Bone Marrow Transplanr (1997) 19:633–635.
   PubMed Web of Science ®Google Scholar
• COLLINS P, WATTS M, BROCKLESBY M, GERRITSEN B, VEYS P: Successful engraftment of haploidentical stem cell transplant for familial haemophagocytic lymphohistiocytosis using both bone marrow and peripheral blood stem cells. BE Haematol (1997) 96:644–646.
   PubMed Web of Science ®Google Scholar
• SCHWINGER W, URBAN C, LACKNER H et al.: Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis. Bone Marrow Transplanr (1998) 22:393–396.
   PubMed Web of Science ®Google Scholar
• JABADO N, DE GRAEFF-MEEDER ER, CAVAZZANA-CALVO M et al: Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically non-identical donors. Blood (1997) 90:4743–4748.
   PubMed Web of Science ®Google Scholar
• IMASHUKU S, HLBI S, TODO S: Hemophagocytic lymphohistiocytosis in infancy and childhood. j Pedtr: (1997) 13:352–357.
   Google Scholar
• STINE KC, SAYLORS RL, SAWYER JR, BECTON DL: Secondary acute myelogenous leukemia following safe exposure to etoposide. I Chia. Oncol (1977) 15:1583–1586.
   Google Scholar
• TAKAHASHI T, YAGASAKI F, ENDO K et al.: Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. Int. j Hematol (1998) 68:333–336.
   PubMed Web of Science ®Google Scholar
• KITAZAWA J, ITO E, ARAI K et al: Secondary acute myeloid leukemia after successful immunochemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol In Press.
   Google Scholar